A double blind intrasubject comparison was made of the effect of treatment with beclomethasone dipropionate (250 rig/puff) and an identical placebo inhaler. The dose used was three puffs (by a Volumatic spacer) taken three times a day for five days, giving a daily total dose of beclomethasone of 2-25 mg. Children were given at least two puffs of a bronchodilator before each trial treatment. Trial inhalers were started at home when the parents recognised the first signs of an acute attack of asthma.
The large and increasing number of preschool children admitted to hospital with acute asthma is a clear demonstration that treatment is unsatisfactory in this age group.' 2 In conjunction with inhaled bronchodilator treatment, corticosteroids have been the mainstay of treatment for acute attacks. Storr and colleagues showed that for children over 2 years old, a single dose of prednisolone was significantly better than placebo in the treatment of acute asthma presenting at a hospital casualty department. 3 A third of their steroid treated group, however, required further steroid treatment. Some young children develop acute attacks of wheezing every three to four weeks in the winter and there is an understandable reluctance to use oral corticosteroids so often.
In order to overcome the problem of frequent oral corticosteroid courses in young children this study was designed to assess the effect of treating acute attacks of asthma with a five day course of high dose inhaled topical steroids, using a spacer device. The aim was to start treatment at the onset of any symptoms suggestive of the beginning of an acute wheezing episode.
Patients and methods

PATIENTS
Thirty five children aged 1-5 years who had experienced at least two episodes of acute wheeze in the preceding three months, were recruited from the children's outpatient departments of Hammersmith, Ashford, and Ealing hospitals ( A double blind intrasubject comparison was made of the effect of treatment with beclomethasone dipropionate (250 rig/puff) and an identical placebo inhaler. The dose used was three puffs (by a Volumatic spacer) taken three times a day for five days, giving a daily total dose of beclomethasone of 2-25 mg. Children were given at least two puffs of a bronchodilator before each trial treatment. Trial inhalers were started at home when the parents recognised the first signs of an acute attack of asthma.
Each recruit was retained in the study until the next four acute episodes had occurred. The treatments were randomised in 'blocks' of two attacks, so that for each pair of attacks, one was treated with the active agent, and the other with the placebo inhaler. The treatment order was randomly determined.
Additional bronchodilator (up to eight puffs given over 10 minutes, or a nebulised aerosol) could be given as considered appropriate. In fact apart from the addition of the trial inhalers the parents and their doctors were encouraged to treat any ensuing symptoms as they had previously, with additional corticosteroids or hospital admission as considered necessary. Thus decoding was unnecessary at any stage during the study.
The parents were asked to record respiratory and systemic symptoms as well as additional treatment, for 14 days from the onset of each new attack, using the diary sheet provided. At the end of this time they recorded their opinion as to the effectiveness of the trial inhaler: helpful/did not help/don't know. The children were then examined in the outpatient clinic, so diaries could be checked and the next trial inhaler provided. For purposes of general management a note of any intercurrent symptoms was made in a separate diary. If any changes had been made to continuous prophylaxis between pairs of acute episodes, only the results obtained from pairs of treatments on the same day to day regime were used in the analysis. The outcome variables which were recorded complete two episodes and were therefore exfor each episode included the need for hospital cluded. Of these, six children did not experience admission or oral corticosteroid treatment, day-two attacks of asthma during the two year trial time and night time symptom scores, additional period, despite their history (mean attack rate bronchodilator usage and parents' assessment of 2-2 episodes in the preceding three months). the efficacy of the trial treatment.
Another five subjects were withdrawn for social Informed consent was obtained from a parent reasons: three because they moved out of the and the study had approval from the ethics area and two whose parents were unable to cope committees of the three hospitals.
with the protocol. Significance of difference NS NS p<002
*Analysis was of discordant pairs only (n=30 pairs). forecast the number of treated episodes and increased above our prediction the number needed to show a treatment difference. This age related change in symptomatology should be borne in mind in future clinical trials in preschool asthma.
The inadequacy ofasthma diaries is recognised by all who attempt clinical trials in asthma. This trial was different from most as it was concerned with acute, and at times very severe symptoms only, in children who generally had prolonged symptom free periods. The scoring system would have perhaps more accurately described the situation if it had expanded the conventional 0-3 range used, to cater for the wide range of symptoms encountered. Also, it was impossible to make an accurate comparison of bronchodilator usage as a variety of dosages and methods of administration were used. The duration and not the amount of additional bronchodilator treatment was therefore used in the analysis and this may not have reflected the severity of the attack.
All except for one of the episodes was described as being associated with acute coryzal symptoms and in most cases fever was also present. This would support the view that acute asthma in this age group is precipitated by viral infections.' Acute wheezing was a major feature in all the children but it is difficult to be certain how much of the symptomatology was additionally caused by bronchitis or post viral cough due to irritant receptor stimulation. The scoring system was not designed to differentiate between 'asthma' and 'non-asthma' symptoms that could coexist. The latter might not be expected to respond to steroid treatment and thus could mask the benefit to symptoms of asthma.
Despite many trials the efficacy of steroids in acute asthma of all ages remains controversial,6 although they are frequently used. Children under 18 months failed to show any benefit in one study but the subjects had been unwell for a mean of seven days before steroids were started. 7 Early treatment has been advocated as being of greater benefit, although the trial on which this advice is based was not controlled.8 Storr et al also failed to show the benefit of a single dose of prednisolone in those under 2 years but showed some improvement in older children,3 as have others using short courses.9 "o All the children in this study were over 18 months and there was no apparent age effect in the response to beclomethasone treatment. Other workers have failed to show any benefit either in children" or in adults.'2 As deaths from asthma have been attributed in part to delay in initiating steroid treatment'3 one has to be careful that failure to show benefit is not simply the result of methodological problems rather than the result of a true lack of response. Intermittent, high dose, inhaled steroid treatment offers a new therapeutic approach to the troublesome condition ofsevere, episodic asthma in young children. Should it be recommended in addition to bronchodilator treatment? Over half of the children in the present study were taking or had tried continuous treatment with either sodium cromoglycate or inhaled steroids and yet they continued to have troublesome frequent attacks. Also, there was no evidence that intermittent high dose beclomethasone was more effective in those taking continuous treatment. Currently available prophylactic treatment is therefore unlikely to be the solution to prevention of acute asthma in this age group. The alternative is the use of single doses or short courses of oral corticosteroids and it remains to be answered whether these are more effective than inhaled topical steroids, and whether frequent oral courses carry any risk of significant adrenal suppression. 
